COMMUNIQUÉS West-GlobeNewswire

Interim Report, Third Quarter 2018, BioPorto Group
08/11/2018
November 8, 2018 Announcement no. 18 Highlights FDA clearance of The NGAL Test™ expected by mid-2019 In the beginning of October 2018, the U.S. Food and Drug Administration (“FDA”) requested additional data from [...]
111, Inc. Announces Third Quarter 2018 Unaudited Financial Results
08/11/2018
SHANGHAI, China, Nov. 08, 2018 (GLOBE NEWSWIRE) -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results [...]
Saniona signs option agreement with Initiator Pharma
08/11/2018
PRESS RELEASE November 8, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it has entered into a 1-year option agreement with Initiator Pharma A/S, where Initiator Pharma obtains [...]
The first patient included in PledPharma’s global Phase III program for PledOx®
08/11/2018
STOCKHOLM, November 8, 2018 — PledPharma AB (publ), a Swedish pharmaceutical developer, today announced that the first patient has been enrolled in the company’s global Phase III program with the company’s drug [...]
Financial calendar 2019
08/11/2018
Orphazyme A/S Company announcement No. 13/2018 Company Registration No. 32266355 Copenhagen, November 8, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
08/11/2018
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg without ABT and 200mg with [...]
VALNEVA Reports Nine Month Results for 2018, Confirms Guidance, Strengthens Balance Sheet with €50m Financing
08/11/2018
Valneva Reports Nine Month Results for 2018, Confirms Guidance, Strengthens Balance Sheet with €50m Financing On track to deliver on multiple key business and R&D milestones €50 million raised in oversubscribed [...]
VALNEVA publie ses résultats pour les neuf premiers mois de l'année 2018, confirme ses prévisions et renforce sa trésorerie avec une récente levée de €50m
08/11/2018
Valneva publie ses résultats pour les neuf premiers mois de l'année 2018, confirme ses prévisions et renforce sa trésorerie avec une récente levée de €50m Validation de multiples jalons opérationnels et R&D en bonne [...]
INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at November 1, 2018
08/11/2018
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT November 1, 2018 Marseille, France, November 8, 2018, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]
INNATE PHARMA : Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er novembre 2018
08/11/2018
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 1 er novembre 2018 Marseille, le 8 novembre 2018, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]
Kiadis Pharma strengthens core team with three senior appointments
08/11/2018
Amsterdam, The Netherlands, November 8, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces that it has [...]
Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST
08/11/2018
Primatene ® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced [...]
Vital Therapies Announces Third Quarter 2018 Financial Results
08/11/2018
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD ® , a cell-based therapy targeting the treatment of acute forms of liver failure, [...]
Precision Optics Corporation Schedules First Quarter Conference Call
07/11/2018
GARDNER, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it intends to release its financial results for the fiscal year 2019 first quarter [...]
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
07/11/2018
New England Journal of Medicine publishes positive detailed results from Praluent ® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001) [...]
Le New England Journal of Medicine publie les résultats positifs détaillés de l'essai clinique consacré à l'effet du Praluent® (alirocumab) sur le risque d'événements cardiovasculaires
07/11/2018
Le New England Journal of Medicine publie les résultats positifs détaillés de l'essai clinique consacré à l'effet du Praluent ® (alirocumab) sur le risque d'événements cardiovasculaires Praluent a significativement [...]
Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
07/11/2018
Zoliflodacin Was Well-Tolerated and Successfully Treated Substantially All Uncomplicated Gonorrhea Cases Phase 3 clinical trial, in partnership with GARDP, to begin in 2019 WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE [...]
BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors
07/11/2018
MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors. Dr. Rietiker was most recently the Chief [...]
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
07/11/2018
Seasoned executive brings more than 20 years of biopharmaceutical industry experience CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company [...]

Pages